ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Actinium-225

Also written as “[225Ac]Ac-FL-261”, “[225Ac]Ac-AKY-2519 (therapeutic)” and “[225Ac]Ac-AKY-1189 (therapeutic)”.

Its studies are mostly in Prostatic Neoplasms · Triple Negative Breast Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 6 companies.

Drug pageActinium-225: every studyMany companies study it; this page follows only the 10 they lead. All 13 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 28, 202510 company-led studies, 8 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aktis Oncology33 open or runningphase 1since May 28, 2025May 28, 2025Dec 2027phase 1 · NCT07020117
Alpha-9 Oncology USAits history only21 open or runningphase 1since Jun 27, 2025Jun 27, 2025Dec 2028phase 1 · NCT07661641
AstraZenecaits history only21 open or runningphase 3since Apr 22, 2026Nov 9, 2018Jun 4, 2029phase 3 · NCT07611110
Eli Lillyits history only11 open or runningphase 1since Jan 3, 2024Jan 3, 2024Sep 2027phase 1 · NCT06229366
Full-Life Technologies UKits history only11 open or runningphase 2since Sep 23, 2026Sep 23, 2026Jun 30, 2030phase 2 · NCT07873450
PeptiDreamits history only11 open or runningphase 1since Jun 17, 2026Jun 17, 2026May 2029phase 1 · NCT07688187

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aktis Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT07020117 · 150 planned · United States
  2. May 6, 2026Phase 1 study in Prostatic NeoplasmsNCT07581184 · 138 planned · United States
  3. Oct 15, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07887971 · 152 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07581184
  2. Dec 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT07020117
  3. Dec 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07887971

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Aktis Oncology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07887971Carcinoma, Non-Small-Cell Lung · United States1RecruitingDec 2028152
NCT07581184Prostatic Neoplasms · United States1RecruitingDec 2027138
NCT07020117Triple Negative Breast Neoplasms · United States1RecruitingDec 2027150

How it is read

Names in the registry

  • “[225Ac]Ac-FL-261”, 3 entries
  • “[225Ac]Ac-AKY-2519 (therapeutic)”, 2 entries
  • “[225Ac]Ac-AKY-1189 (therapeutic)”, 1 entry
  • “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”, 1 entry
  • “[Ac-225]-PSMA-62 (mCRPC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.